

Newsletter articles about drugs covered under the medical benefit

For Blue Cross commercial

Revised November 2024

This document contains links to newsletter articles about drugs covered under the medical benefit.

The Record, October 2024

- [Oncology medical drug management moving to OncoHealth for most members Jan. 1](#)
- [Zynyz, Talvey will require prior authorization for URMBT members with Blue Cross non-Medicare plans](#)

The Record, September 2024

- [Guidelines for billing Avastin for Blue Cross, BCN commercial members](#)
- [Tyenne, Tofidence, Zinplava to have site-of-care requirement for most commercial members, starting Nov. 1](#)

The Record, August 2024

- [We're changing how we manage immunoglobulin therapies for most commercial members, starting Oct. 1](#)
- [Reminder: Bill HCPCS code J3590 for off-label intravitreal use of Avastin for Blue Cross commercial members](#)
- [Vyjuvek has additional requirements for most commercial members](#)
- [We're adding requirements for Lamzede, Vyjuvek for URMBT members with Blue Cross non-Medicare plans](#)
- [New Alyglo requirements for Federal Employee Program non-Medicare members](#)

The Record, July 2024

- [Changes coming for select weight loss drugs for some commercial members](#)
- [Requirements, codes changed for some medical benefit drugs](#)
- [Soliris, Ultomiris to require step therapy for commercial members](#)
- [Hemlibra has a quantity limit requirement for most commercial members](#)
- [Loqtorzi to have requirements for most members, starting Aug. 15](#)
- [Syfovre, Izervay, Elfabrio to have requirements for URMBT members with non-Medicare plans](#)
- [Article correction: Spevigo SC has requirements for most commercial members, starting April 25](#)
- [AllianceRx Walgreens Pharmacy to become Walgreens Specialty Pharmacy on Aug. 1](#)

The Record, June 2024



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Newsletter articles about drugs covered under the medical benefit

For Blue Cross commercial

Revised November 2024

- [AllianceRx Walgreens to become exclusive specialty drug pharmacy for MESSA, starting July 1, 2024](#)
- [Additional drugs to have a site-of-care requirement for some commercial members, starting Aug. 1](#)
- [Amtagvi has additional requirements for most commercial members](#)
- [We're granting a 90-day extension to the time limit for commercial claim submission](#)
- [Omvo SC and IV to have step therapy requirement for most commercial members](#)
- [Cosentyx IV to have a site-of-care requirement for most commercial members, starting July 1](#)
- [Pemfexy and Pemrydi RTU to have additional step therapy requirements for most members](#)
- [Spevigo SC now has requirements for most commercial members](#)
- [Vyjuvek now has site-of-care requirement for most commercial members](#)

The Record, May 2024

- [Requirements and codes changed for some medical benefit drugs](#)
- [Elrexio, Talvey to require prior authorization for most members, starting June 20](#)
- [Columvi, Daxxify, Qalsody to require prior authorization for URMBT members with Blue Cross non-Medicare plans](#)
- [Cinryze, Elfabrio, Evkeeza to have site-of-care requirement for most commercial members, starting July 1](#)
- [Udenyca Onbody to require prior authorization for most commercial members effective immediately](#)
- [Most commercial members must try preferred product for Zynteglo](#)

The Record, April 2024

- [Starting April 1, additional preferred product required for Soliris, Ultomiris for most commercial members](#)

The Record, March 2024

- [Requirements and codes changed for some medical benefit drugs](#)
- [Omvo SC to have a site-of-care requirement for most commercial members starting in May](#)
- [Cabenuva to have requirements for most commercial members, starting May 1](#)
- [Pemfexy to have step therapy requirements starting in April](#)

The Record, February 2024



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Newsletter articles about drugs covered under the medical benefit

For Blue Cross commercial

Revised November 2024

- [Additional drugs to have site-of-care requirements for some commercial members starting in March](#)
- [Rystiggo to have site-of-care requirement for most commercial members starting in April](#)
- [Additional drugs to have requirements for URMBT members with Blue Cross non-Medicare plans](#)
- [Additional drugs to require prior authorization for Federal Employee Program non-Medicare members](#)
- [FDA withdrawal of Makena approval affects FEP members](#)

The Record, January 2024

- [Additional medical oncology drugs to have requirements for most members](#)